Bob Clay BPharm, MSc, MBA

Bob graduated in Pharmacy from the University of Bath in 1980 and subsequently completed an MSc in BioPharmacy, from the University of London, and an MBA, from the Open University. Following completion of his professional training in hospital pharmacy he joined the pharmaceutical industry as a formulation scientist at the UK laboratories of Rhone-Poulenc. Later, he joined the UK Licensing Authority as a pharmaceutical assessor and has held regulatory affairs leadership roles with several pharmaceutical companies including Wellcome, Zambon, Pfizer and AstraZeneca. Bob was Chief Regulatory Officer at Kinapse, a leading CRO in outsourcing to the biopharma industry. ​​

Bob has experience across the development continuum from research through commercialisation, leading regulatory projects throughout the product lifecycle. He has led projects in wide range of therapeutic areas through EU centralised and mutual recognition procedures and global development programmes. He has a strong interest in the impact of regulation on the development of innovative medicines and healthcare policy matters.

Bob is a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture (MMV) and several working groups at CPTR (Critical Path for TB Regimens). Bob joined the board of TOPRA in January 2014 and is President for 2017.​